BioTech Industry Overview |
|
Global | Amount | Units | Year | Source |
Public & Private Biotech Companies | 4,717 | Companies | 2008 | E&Y |
Public Biotech Companies | 776 | Companies | 2008 | E&Y |
Number of Employees | 200.7 | Thousand | 2008 | E&Y |
Biotech Revenues | 89.7 | Bil. US$ | 2008 | E&Y |
Increase from 2007 | 12 | % | 2008 | E&Y |
R&D Expenses | 31.7 | Bil. US$ | 2008 | E&Y |
Net Income | -1.4 | Bil. US$ | 2008 | E&Y |
Total Biotech Company Financing | 16.0 | Bil. US$ | 2008 | E&Y |
Venture Financing | 6.0 | Bil. US$ | 2008 | E&Y |
Total Pharmaceutical Sales, Worldwide | 773.1 | Bil. US$ | 2008 | IMS |
Total R&D Expenses, PhRMA Member Companies | 47.9 | Bil. US$ | 2008 | PhRMA |
Total R&D Expenses, All Pharmaceutical Companies | 65.2 | Bil. US$ | 2008 | Burrill |
U.S. |
Public & Private Biotech Companies | 1,754 | Companies | 2008 | E&Y |
Public Biotech Companies | 371 | Companies | 2008 | E&Y |
Revenues | 66.1 | Bil. US$ | 2008 | E&Y |
% Increase | 8 | % | 2008 | E&Y |
R&D Expenses | 25.3 | Bil. US$ | 2008 | E&Y |
Net Income | 0.4 | Bil. US$ | 2008 | E&Y |
Number of Employees | 128.2 | Thousand | 2008 | E&Y |
Venture Financing | 4.5 | Bil. US$ | 2008 | E&Y |
Area of Biotech Crops | 62.5 | Mil. Hectares | 2008 | ISAAA |
Prescription Drug Sales, Domestic | 291.0 | Bil. US$ | 2008 | IMS |
Number of FDA Approvals for New Drugs (NDAs) | 88 | Approvals | 2008 | FDA |
Number of Approvals for New Molecular Entities (NMEs) | 24 | Approvals | 2008 | FDA |
Patents Granted for "Multicellular Living Organisms & Unmodified Parts Thereof & Related Processes" | 762 | Patents | 2008 | USPTO |
Pharmaceutical Industry Funding, NIH | 30.4 | Bil. US$ | 2009 | NIH |
Total Requested Budget for Biological Science Research, U.S. (NSF) | 733.0 | Mil. US$ | 2010 | NFS |
Mean Annual Salary for Biochemists & Biophysicists | 88,450 | US$ | May-08 | BLS |
Average Cost of Developing a Biologic Drug | 1.2 | Bil. US$ | 2005 | Tufts |
| PhRMA1 Member Statistics, U.S. |
Pharmaceutical Sales, Domestic | 189.3 | Bil. US$ | 2008 | PhRMA |
% Generic (by volume) | 72 | % | 2008 | PhRMA |
Pharmaceutical Sales, Foreign2 | 99.0 | Bil. US$ | 2008 | PhRMA |
Pharmaceutical R&D Spending, Domestic | 38.4 | Bil. US$ | 2008 | PhRMA |
as a Percentage of All Sales | 20.3 | % | 2008 | PhRMA |
Share of R&D Spending by Function: |
Prehuman/Preclinical | 27.3 | % | 2007 | PhRMA |
Phase I | 7.4 | % | 2007 | PhRMA |
Phase II | 13.0 | % | 2007 | PhRMA |
Phase III | 28.5 | % | 2007 | PhRMA |
Approval | 5.0 | % | 2007 | PhRMA |
Phase IV | 13.4 | % | 2007 | PhRMA |
Uncategorized | 5.2 | % | 2007 | PhRMA |
| 1 PhRMA = Pharmaceutical Research and Manufacturers Association, a group of leading pharmaceutical and biotechnology companies in the U.S. 2 Not including foreign divisions of foreign companies. |
| E&Y = Ernst & Young; IMS = IMS Health; Burrill = Burrill & Company; ISAAA = International Service for the Acquisition of Agri-Biotech Applications; Tufts = Tufts Center for the Study of Drug Development; FDA = U.S. Food & Drug Administration; USPTO = U.S. Patent & Trademark Office; NIH = U.S. National Institutes of Health; NSF = U.S. National Science Foundation; BLS = U.S. Bureau of Labor Statistics |
Source: Plunkett Research, Ltd. Plunkett's Biotech & Genetics Industry Almanac 2010
Copyright© 2009, All Rights Reserved |